Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer

Cancer Science

Volumn 101, Issue 11, 2010, Pages 2436-2442

  Kim, Min ^a   Kang, Hyo Gyoung ^b   Lee, Shin Yup ^a   Lee, Hyung Cheol ^b   Lee, Eung Bae ^a   Choi, Yi Young ^b   Lee, Won Kee ^b   Cho, Sukki ^a   Jin, Guang ^b   Jheon, Hyo Sung ^b   Son, Ji Woong ^c   Lee, Myung Hoon ^b   Jung, Deuk Kju ^b   Cha, Seung Ick ^a   Kim, Chang Ho ^a   Kang, Young Mo ^a   Kam, Sin ^b   Jung, Tae Hoon ^a   Jheon, Sanghoon ^d   Park, Jae Yong ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Konyang University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA REPAIR; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 77958590151     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01699.x     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Miller YE. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 2005; 33: 216-23.
3. Zhang X, Miao X, Sun T et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005; 42: 479-84.
4. Park JY, Park JM, Jang JS et al. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Human Mol Genet 2006; 15: 1963-71.
5. Heist RS, Zhou W, Chirieac LR et al. MDM2 polymorphism, survival, and histology in early-stage non-small cell lung cancer. J Clin Oncol 2007; 25: 2243-7.
6. Heist RS, Zhai R, Liu G et al. VEGF polymorphisms and survival in early-stage non-small cell lung cancer. J Clin Oncol 2008; 26: 856-62.
7. Yoo SS, Choi JE, Lee WK et al. Polymorphisms in the CASPASE genes and survival in patients with early stage non-small cell lung cancer. J Clin Oncol 2009; 27: 5823-9.
8. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
9. Ronen A, Glickman BW. Human DNA repair genes. Environ Mol Mutagen 2001; 37: 241-283.
10. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
11. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
12. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-89.
13. Matullo G, Dunning AM, Guarrera S et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006; 27: 997-1007.
14. Lotkionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004; 208: 1-33.
15. Spitz MR, Wu X, Wang Y et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354-7.
16. Sakano S, Matsumoto H, Yamamoto Y et al. Association between DNA repair gene polymorphisms and p53 alterations in Japanese patients with muscle-invasive bladder cancer. Pathobiology 2006; 73: 295-303.
17. Candiloro LM, Dobrobic A. Detection of MGMT methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res 2009; 2: 862-7.
18. Bernardes de Jesus BM, Bjoras M, Coin F et al. Dissection of the molecular defects caused by pathogenic mutations in the DNA repair factor XPC. Mol Cell Biol 2008; 28: 7225-35.
19. Shen J, Desai M, Agrawal DO et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1614-9.
20. Zhu Y, Yang H, Chen Q et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair 2008; 7: 141-8.
21. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002; 17: 463-9.
22. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a huge review. Am J Epidemiol 2005; 161: 1-14.
23. Tubbs JL, Pegg AE, Tainer JA. DNA binding, nucleotide flipping, and helix-turn-helix motif in base repair by O-alkylguanine-DNA alkyltransferase and its implication for cancer chemotherapy. DNA Repair 2007; 6: 1100-15.
24. Inoue R, Abe M, Nakabeppu Y et al. Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics 2000; 10: 59-66.
25. 6-methylguanine-DNA-methlytransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK. Pharmacogenet Genomics 2005; 15: 571-8.
26. Mori Y, Shiwaku H, Fukushige S et al. Alternative splicing of hMSH2 in normal human tissues. Hum Genet 1997; 99: 590-5.
27. Jung CY, Choi JE, Park JM et al. Polymorphisms in the hMSH2 gene and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 762-8.
28. Kim JG, Chae YS, Sohn SK et al. IVS10+12A>G polymorphism in hMSH2 gene associated with prognosis for patients with colorectal cancer. Ann Oncol 2010; 21: 525-9.
29. Masutani M, Nakagama H, Sugimura T. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease. Cell Mol Life Sci 2005; 62: 769-83.
30. Lockett KL, Hall MC, Xu J et al. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004; 64: 6344-8.
31. Hao B, Wang H, Zhou K et al. Identification of genetic variants in base excision repair pathways and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004; 64: 4378-84.
32. Zhang X, Miao X, Liang G et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005; 65: 722-26.
33. Li C, Hu Z, Lu J et al. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer 2007; 110: 867-75.
34. Li C, Liu Z, Wang LE et al. Genetic variants of the ADPRT, XRCC1, and APE1 genes and risk of cutaneous melanoma. Carcinogenesis 2006; 27: 1894-1901.
35. Zhai X, Liu J, Hu Z et al. Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women: a case-control study. Oncol Rep 2006; 15: 247-52.
36. Tuimala J, Szekely G, Gundy S et al. Genetic polymorphisms of DNA repair and xenobiotics-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 2002; 23: 1003-8.
37. Schneider J, Classen V, Helmig S. XRCC1 polymorphism and lung cancer risk. Expert Rev Mol Diagn 2008; 8: 761-780.
38. Lin PI, Vance JM, Pericak-Vance MA et al. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007; 80: 531-8.